News

Apr 24, 2025

Mabwell to Present Clinical Data of 9MW2821 Combined with Toripalimab in Patients with UC in an Oral Presentation at 2025 ASCO

➞

Apr 14, 2025

Mabwell and DP Technology Announces Strategic Cooperation to Build a New Research Paradigm for R&D of Innovative Drug

➞

Apr 02, 2025

Mabwell Announces NMPA Approval to Initiate Clinical Trial of novel B7-H3-targeting ADC for Advanced Solid Tumors in Combination with PD-1 Inhibitor

➞

Mar 27, 2025

Mabwell and Insilico Medicine Announce Strategic Collaboration to Empower R&D of ADC with AI

➞

Mar 26, 2025

Mabwell to Present results of 6 studies at the 2025 American Association for Cancer Research (AACR) Annual Meeting

➞

Feb 19, 2025

Mabwell publishes the preclinical research results of integrin-αvβ8-targeting antibody in the renowned journal

➞

Jan 09, 2025

Mabwell's Nectin-4 Targeted ADC 9MW2821 Combination Therapy Demonstrates 87.5% ORR and Granted CDE Breakthrough Therapy Designation

➞